Class 9
New York – Batch 09
Undo See the concurrent SF batch Contact Us for an
Early Intro
Mothership Materials
Ag waste to power the bioeconomy
Agricultural waste accounts for up to 10% of global greenhouse gas emissions—more than air and car travel combined.

Capturing new ingredients by molecularly upcycling agricultural waste, paving the way for a sustainable, circular, and traceable bioeconomy.

Jo Marini, Co-Founder and CEO of Mothership Materials
“The bioeconomy is growing faster than its supply chain. Companies need feedstocks that don’t compete with food systems or rely on fossil fuels. We’re here to unlock that missing piece—turning agricultural waste into low-cost, carbon-negative inputs.”
Mothership Materials has raised $275,000 from SOSV IndieBio.
Mothership Materials
Jo Marini, Co-Founder and CEO of Mothership Materials
“The bioeconomy is growing faster than its supply chain. Companies need feedstocks that don’t compete with food systems or rely on fossil fuels. We’re here to unlock that missing piece—turning agricultural waste into low-cost, carbon-negative inputs.”
Mothership Materials has raised $275,000 from SOSV IndieBio.
Semion
Restoring crops' ability to defend against pests
In Argentina, warming temperatures have increased corn leafhopper populations and allowed them to reach new areas. During the 23/24 season, corn yields fell by 20% on average, resulting in a $2.2 billion loss. The pest is beginning to spread into the U.S.

Activating plant defense mechanisms silenced during the process of domestication to develop novel pest control solutions.

Emilio Molina, Co-Founder & CEO
“I’m the third generation of a farming family and started this company after witnessing the destruction that pests caused to my father’s farm. Helping farmers thrive is my purpose, and it’s what I want to dedicate my life to.”
Semion has raised $275,000 from SOSV IndieBio.
Semion
Emilio Molina, Co-Founder & CEO
“I’m the third generation of a farming family and started this company after witnessing the destruction that pests caused to my father’s farm. Helping farmers thrive is my purpose, and it’s what I want to dedicate my life to.”
Semion has raised $275,000 from SOSV IndieBio.
Tinkeso Therapeutics
Cell therapy for oncology and autoimmune diseases.
The global oncology drugs market is expected to grow from $231 billion in 2024 to over $532 billion in 2031, driven by demand for more targeted therapies.

Novel allogeneic Natural Killer T (NKT) cell therapies for oncology and autoimmune diseases.

Emmie Fan, Co-Founder and CEO of Tinkeso Therapeutics
“The human immune system has a greater ability to fight off cancer and autoimmune diseases than we realize. With natural killer T (NKT) therapies, Tinkeso is harnessing that ability for patients with some of the most difficult-to-treat cancers.”
Tinkeso Therapeutics
Emmie Fan, Co-Founder and CEO of Tinkeso Therapeutics
“The human immune system has a greater ability to fight off cancer and autoimmune diseases than we realize. With natural killer T (NKT) therapies, Tinkeso is harnessing that ability for patients with some of the most difficult-to-treat cancers.”
Quorum Earth
Biopesticides made from fungi
Pollinators, including bees, butterflies, and more, boost global crop production by $237-$577 billion yearly. However, the varroa mite, now present on every continent with significant honeybee populations, poses a major threat to these essential pollinators and the agricultural benefits they provide.

Using the power of the fungal kingdom to develop non-toxic biopesticides to save the bees.

Chris Kantrowitz, Co-Founder and CEO
“Varroa mites are a huge problem because we die if bees die. It comes down to that.”
Quorum Earth has raised $275,000 from SOSV IndieBio.
Quorum Earth
Chris Kantrowitz, Co-Founder and CEO
“Varroa mites are a huge problem because we die if bees die. It comes down to that.”
Quorum Earth has raised $275,000 from SOSV IndieBio.
NanoPlume
Bio-based super insulation
Heating and cooling account for roughly half of global energy consumption and are responsible for more than 40% of energy-related CO2 emissions.

Manufacturing the next generation of ultra-insulating, affordable, bio-based aerogels to maximize energy efficiency across multiple industries.

Theresa Hoffmann, Co-Founder and CEO
"Insulation has not been a sexy topic, but it is a universal necessity, touching every aspect of our daily lives. NANOPLUME aims to replace the world’s outdated insulation technologies with bio-based aerogels that are energy-efficient, space-efficient, and upcycled from plentiful waste streams."
NANOPLUME has raised $525,000 from SOSV IndieBio and the Genesis Consortium.
NanoPlume
Theresa Hoffmann, Co-Founder and CEO
"Insulation has not been a sexy topic, but it is a universal necessity, touching every aspect of our daily lives. NANOPLUME aims to replace the world’s outdated insulation technologies with bio-based aerogels that are energy-efficient, space-efficient, and upcycled from plentiful waste streams."
NANOPLUME has raised $525,000 from SOSV IndieBio and the Genesis Consortium.
Bactery
Green energy, right at your feet
As of 2024, an estimated 225 million sensors have been sold for use in precision agriculture. They rely on single-use batteries or high-maintenance solar systems.

Capturing green energy generated by bacteria found in soil for remote sensors and IoT devices.

Dr. Jakub Dziegielowski, Founder and CEO
"Bactery’s ambition is to not just be a sensor battery company but to develop a platform with many applications in rural and urban electrification. As we continue to upscale our power densities, the doors will open to those possibilities."
Bactery has raised $275,000 from SOSV IndieBio.
Bactery
Dr. Jakub Dziegielowski, Founder and CEO
"Bactery’s ambition is to not just be a sensor battery company but to develop a platform with many applications in rural and urban electrification. As we continue to upscale our power densities, the doors will open to those possibilities."
Bactery has raised $275,000 from SOSV IndieBio.
heXembio
Rejuvenating human blood cells for improved healthspan.
In the United States, people over the age of 55 account for over 55% of healthcare spending—about $2.5 trillion annually.

Rejuvenating human blood cells for improved healthspan.

Gabriel Levesque-Tremblay, co-founder and CEO
“This is a trillion-dollar market because we're talking about the rejuvenation of almost any adult and the potential to treat or prevent 20 diseases. We are proud to push the boundaries of possibilities in the human longevity space.”
heXembio has raised $1,025,000 from SOSV IndieBio and the Genesis Consortium.
heXembio
Gabriel Levesque-Tremblay, co-founder and CEO
“This is a trillion-dollar market because we're talking about the rejuvenation of almost any adult and the potential to treat or prevent 20 diseases. We are proud to push the boundaries of possibilities in the human longevity space.”
heXembio has raised $1,025,000 from SOSV IndieBio and the Genesis Consortium.
Asta Bio
Reimagining Cancer Treatment with Targeted Radiotherapy
18 million cancer patients are diagnosed each year worldwide, with the majority suffering from advanced metastatic disease. About 90% of patients living with metastatic cancer will die of it.

Our technology combines 211-Astatine, the most druggable alpha-emitting radioisotope, with multivalent single-domain antibodies to deliver potent alpha radiation that breaks DNA strands and kills the tumor cells while leaving normal cells unaffected.

Ahmad-Reza Saadat, Co-Founder and CEO
“Radiation is one of the most effective tools we have to treat cancer. The challenge is harnessing that power to target tumors more precisely without harming the patient and to make it more widely available. That’s what we're doing.”
Asta Bio has raised $525,000 from SOSV IndieBio and the Genesis Consortium.
Asta Bio
Ahmad-Reza Saadat, Co-Founder and CEO
“Radiation is one of the most effective tools we have to treat cancer. The challenge is harnessing that power to target tumors more precisely without harming the patient and to make it more widely available. That’s what we're doing.”
Asta Bio has raised $525,000 from SOSV IndieBio and the Genesis Consortium.
Giraffe Bio
Upcycling Critical Minerals
Mining generates over 100 billion tons of waste annually and accounts for 4% of global energy use—much of it grinding ores. About 70% of copper reserves remain trapped in low-grade ores, and by 2035, copper supplies are projected to fall 31% short of demand.

Data-driven biomolecular design to boost the efficiency and sustainability of mining for critical minerals.

Alejandro Buffo Sempé, Co-Founder and CEO
"By enhancing yields and unlocking value from previously uneconomical resources, Giraffe Bio is reshaping mining. Through innovations in biology, hardware, and AI, we are enabling a more efficient and sustainable way to meet the rising demand for critical minerals."
Giraffe Bio has raised $525,000 from SOSV IndieBio and the Genesis Consortium.
Giraffe Bio
Alejandro Buffo Sempé, Co-Founder and CEO
"By enhancing yields and unlocking value from previously uneconomical resources, Giraffe Bio is reshaping mining. Through innovations in biology, hardware, and AI, we are enabling a more efficient and sustainable way to meet the rising demand for critical minerals."
Giraffe Bio has raised $525,000 from SOSV IndieBio and the Genesis Consortium.